Reply
2013 | 2014
Bayer AG
c/o Finger Marketing Services
ostfach
euss
Germany
Place stamp
here
edition
lease fill out in loc letters
Name
First name
Street address
Postal code / city
Country
Email
Phone
S
ES | FA
ES | F G
NA
45
Masthead
Contents
Contents
MASTHEAD
Published by
Bayer AG, Communications, 51368 Leverkusen, Germany
BAYER
Editor GROUP
Dr. Katrin Schneider, phone +49 214 30 48825
Email: [email protected]
Mission and Values
Organization
English edition
Board
of Management
Currenta
GmbH & Co. OHG
Supervisory
Board, Corporate Governance
Language Service
Sites and Regions
Business
Bayer on Development
the internet
Investor
Information
www.bayer.com
More than 30,000 people attended a grand celebration of Bayer’s
150 th anniversary in the BayArena stadium. Employees, their families
and retirees had traveled to Leverkusen from all over Germany to attend.
During the event, they formed the largest-ever human Bayer cross.
since 1863 – innovating for the future
With our inventions we have contributed much to improving
people’s lives since 1863. To mark its anniversary, Bayer is holding
a series of events and organizing a number of projects worldwide.
While these activities focus primarily on the employees and their
families, Bayer is also celebrating with neighbors, customers,
partners and the scientific community. Find out more about Bayer’s
anniversary on the internet at www.bayer.com.
150
2
4
6
8
10
12
14
August 2013
SUBGROUPS AND SERVICE COMPANIES
Bayer HealthCare
Bayer CropScience
Bayer MaterialScience
Service Companies
16
20
24
28
OTHER TOPICS
Research and Development
Employees
Sustainable Development
History
Dialogue
Masthead
ye a rs
Forward-Looking Statements
This publication may contain forward-looking statements based on current assumptions
and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the
actual future results, financial situation, development or performance of the company and
the estimates given here. These factors include those described in Bayer‘s public reports,
which are available on the Bayer website at www.bayer.com. The company assumes no
liability whatsoever to update these forward-looking statements or to conform them to
future events or developments.
Legal Notice
The product names designated with ™ are brands of the Bayer Group or its distribution
partners and are registered trademarks in many countries.
30
32
34
38
42
45
1
2
Mission and Values
Bayer Names | Figures | Facts
Mission and Values
“Bayer: Science For A Better Life”
Bayer is a world-class innovation company.
Our scientific achievements aim to help
improve people’s lives by addressing the
great challenges of our time – the growing
world population, an aging society and the
need to use natural resources more
efficiently.
Bayer AG headquarters in Leverkusen
• Throughout the world we are preventing, alleviating or curing diseases and
improving diagnostic techniques.
• We are helping to provide an adequate
supply of high-quality food, feed and
plant-based raw materials.
• Our high-tech materials are making
significant contributions in a variety of
areas such as energy and resource
efficiency, mobility, construction and
home living.
We have spent many decades laying the foundations for achieving these goals and are the only global company to combine
expertise in human, animal and plant health and in high-tech
materials. Our focus on innovation is the key to maintaining or
achieving leadership positions in all of our markets. It is also
about creating value – for our customers, stockholders and
employees, while at the same time considering the needs of
other stakeholders in society.
We are committed to operating sustainably and addressing our
social and ethical responsibilities as a corporate citizen. Our
ayer values of eadership, nte rity, le i ility and fficiency
– represented by the acronym life – guide our actions as we
work to accomplish our mission “Bayer: Science For A Better
Life.”
www.bayer.com > about bayer > mission & values
3
4
Organization
Bayer Names | Figures | Facts
Organization
BUSINESS AREAS
Bayer HealthCare
ayer
defines the common values, oals and strate ies for
the entire Group. The three subgroups and three service companies operate independently, led by the management holding
company. The Corporate Center supports the Group Management Board in its task of strategic leadership.
BAYER AG (HOLDING COMPANY )
Group Management Board
Marijn Dekkers
Chairman
hief ecutive fficer
hief inancial fficer
Animal Health
Consumer Care
Medical Care
Pharmaceuticals
Global Drug Discovery
Global Development
Product Supply
Global Business Development & Licensing
General Counsel
Human Resources
Communications and Public Affairs
W. Plischke **
M. Vehreschild
D. Ehle
E. L. Mann
A. Main
A. Fibig
A. Busch
K. Malik
H. Klusik *
N. Sheail
S. Gehring
A. Günther
O. Renner
Bayer CropScience
Werner Baumann
Finance
Wolfgang Plischke
Technology, Innovation & Sustainability
Michael König *
Human Resources
L. Condon
M. A. Schulz
L. van der Broek
M. Haug
S. Kurzawa
G. Marchand
C. D. Nicholson
A. Noack *
G. Riemann
M. Kremer
G. Marchant
hief ecutive fficer
hief inancial fficer
hief peratin
fficer
Human Resources
Communications
General Counsel
Research & Development
Product Supply
Environmental Science
Strategy
Business Management
Bayer MaterialScience
Corporate Center Departments
orporate ffice
P. Molan
Finance
P. Müller
Corporate Communications &
Government Relations
H. Heitmann
Taxes
B. - P. Bier
Investor Relations
A. Rosar
Mergers & Acquisitions
F. Rittgen
hief ecutive fficer
hief inancial fficer
Industrial Operations
Polycarbonates
Polyurethanes
Coatings, Adhesives, Specialties
Law, Patents & Compliance
Human Resources
Communications and Public Affairs
P. Thomas
A. Steiger-Bagel
T. Van Osselaer
M. Steilemann
J. Wolff
D. Meyer
G. Harnier
M. Bernhardt *
R. Northcote
Environment & Sustainability
W. Grosse Entrup
SERVICE AREAS
Law, Patents & Compliance
R. Hartwig
Corporate Human Resources &
Organization
H. - U. Groh
Bayer Business
Services
Bayer Technology
Services
Currenta
Regional Coordination
I. Paterson
Corporate Development
A. Moscho
D. Hartert
Chairman of the
Executive Board
W. Oehlschläger *
Member of the
Executive Board
D. Van Meirvenne
Managing Director
G. Hilken
Chairman of the
Executive Board
J. Waldi *
Member of the
Executive Board
Corporate Auditing
R. Meyer
Group Accounting & Controlling
U. Hauck
* Labor Director
As of September 1, 2013
** Dr. Jörg Reinhardt ended his active service with Bayer on February 28, 2013.
Professor Wolfgang Plischke has taken over the function of Chairman at Bayer HealthCare in
addition to his existing duties until a successor is appointed.
5
6
Board of Management of Bayer AG
Bayer Names | Figures | Facts
Board of Management
of Bayer AG
DR. MARIJN DEKKERS
Chairman of the Board of Management
Born in 1957 in the Dutch city of Tilburg, Dekkers studied chemistry
and chemical engineering in Nijmegen and Eindhoven. After gaining a
Ph.D., he began a career in research with General Electric in the United
States. Having held various positions in the United States, latterly as
hief ecutive fficer and resident of hermo isher cientific nc ,
e ers too over as ayer hief ecutive fficer in cto er 2010.
WERNER BAUMANN
Finance ·
Europe and North America regions
Born in Krefeld, Germany, in 1962, Werner Baumann studied economics
in Aachen and Cologne. He joined Bayer AG in 1988, here his first
duties were in the Corporate Finance Department. After holding positions in Spain and the United States, he became a member of the Board
of Management of Bayer HealthCare and its Labor Director. Baumann
as appointed hief inancial fficer of ayer in ay 2010.
PROF. WOLFGANG PLISCHKE
Technology · Innovation · Sustainability ·
Asia / Pacific region
Born in Stuttgart. Germany, in 1951, Wolfgang Plischke studied biology
at the University of Hohenheim. Having gained a Ph.D., Plischke began
his career with Bayer at the subsidiary Miles in 1980. After holding a
number of positions in Germany and abroad, he became Head of the
harmaceuticals usiness roup, first in orth merica and then orldwide. He was appointed to the Board of Management in March 2006.
MICHAEL KÖNIG
Human Resources · Labor Director ·
Latin America / Africa / Middle East region
Michael König was born in Iserlohn, Germany, on September 3, 1963.
He studied chemical process engineering in Dortmund, joining Bayer in
1990 as a process engineer for chemicals projects in Europe. After holding a number of management positions at Bayer MaterialScience, he
was appointed to the Board of Management of Bayer AG effective April
1, 2013 and succeeded Dr. Richard Pott with effect from June 1, 2013.
7
8
Supervisory Board, Corporate Governance
Bayer Names | Figures | Facts
Supervisory Board,
Corporate Governance
Other members of the Supervisory Board
Dr. Paul Achleitner
Chairman of the Supervisory Board of Deutsche Bank AG
Dr. Clemens Börsig
Member of various supervisory boards
The role of the 20-member Supervisory Board of Bayer AG is to
oversee and advise the Board of Management. Under the German Codetermination Act, half the members of the Supervisory
Board are elected by the stockholders, and half by the company’s
employees. The Supervisory Board is directly involved in decisions on matters of fundamental importance to the company and
confers with the Board of Management on the company’s strategic alignment. It also holds regular discussions with the Board of
Management on the company’s business strategy and the status
of its implementation.
André van Broich
Chairman of the Works Council of the Dormagen site of Bayer
Thomas Ebeling
hief ecutive fficer of ro ie en at
edia
Dr.-Ing. Thomas Fischer
Chairman of the Group Managerial Employees’ Committee of Bayer
Peter Hausmann
Member of the Executive Committee of the German Mining,
Chemical and Energy Industrial Union
The Supervisory Board has set up four committees – the Presidial Committee, the Audit Committee, the Human Resources Committee and the Nominations Committee – and entrusted them
with certain tasks in accordance with the German Stock Corporation Act and the German Corporate Governance Code.
Reiner Hoffmann
North Rhine District Secretary of the German Mining,
Chemical and Energy Industrial Union
Yüksel Karaaslan
Chairman of the Works Council of the Berlin site of Bayer
Dr. rer. pol. Klaus Kleinfeld
hairman and hief ecutive fficer of lcoa nc
CORPOR ATE GOVERNANCE
Bayer has always placed great importance on responsible
corporate governance. In 2012 the company was able to issue a
declaration that it had complied with the recommendations of
the German Corporate Governance Code in the past with one
temporary exception and was now fully compliant again.
Petra Kronen
Chairman of the Works Council of the Uerdingen site of Bayer
Dr. rer. nat. Helmut Panke
Member of various supervisory boards
Sue H. Rataj
Member of the Board of Directors (non-executive) of Cabot Corporation
Petra Reinbold-Knape
Northeast District Secretary of the German Mining, Chemical
and Energy Industrial Union
www.bayer.com > about bayer > corporate governance
www.bayer.com > about bayer > supervisory board
Michael Schmidt-Kiessling
Vice Chairman of the Works Council of the Wuppertal site of Bayer
GOVERNANCE BODIES
Chairman of the Supervisory Board
Prof. Dr.-Ing. Ekkehard D. Schulz
Member of various supervisory boards
Werner Wenning
Dr. Klaus Sturany *
Member of various supervisory boards
Prof. Dr. Dr. h. c. mult. Ernst-Ludwig Winnacker
Secretary General of the Human Frontier Science Program
Vice Chairman of the Supervisory Board
Oliver Zühlke
Chairman of the Works Council of the Leverkusen site of Bayer
Thomas de Win
Chairman of the Bayer Central and Group Works Councils
*
independent expert member pursuant to Section 100 Paragraph 5 of the German Stock
Corporation Act (AktG)
9
10
Sites and Regions
Bayer Names | Figures | Facts
Sites and Regions
NORTH AMERICA
EUROPE
Sales
€9,576 million, (+17.1%) *
Sales
€14,730 million, (+2.0%) *
Employees
15,300
Employees
52,300
R&D expenses
€588 million
R&D expenses
€2,198 million
Companies
46 **
Companies
143 ***
www.bayer.com > about bayer > bayer worldwide
The Bayer Group is a
global enterprise with
companies in nearly
every country. The
map shows some of its
principal sites, with
key data for 2012 in
the boxes.
LATIN AMERICA / AFRICA / MIDDLE EAST
ASIA / PACIFIC
Sales
€6,688 million, (+10.2%) *
Sales
€8,766 million, (+11.8%) *
Employees
16,200
Employees
26,700
R&D expenses
€41 million
R&D expenses
€186 million
Companies
45 **
Companies
57 **
*
**
***
2012 sales by market (change from 2011)
fully consolidated subsidiaries (as of December 31, 2012)
Bayer AG and consolidated companies (as of December 31, 2012)
11
12
Business Development
Bayer Names | Figures | Facts
Business Development
Key Data
€ million
€ million
%
€ million
he ayer roup re sales as e pected in the first half of 2013.
ebitda before special items, however, was only slightly above
the prior-year period. While the Life Sciences businesses
(Bayer HealthCare and Bayer CropScience) posted pleasing
gains in sales and earnings, business development at Bayer
aterial cience as ea in a difficult mar et environment
Sales
20,220
20,626
+ 2.0
39,741
EBIT 1
2,371
3,058
+ 29.0
3,928
EBIT before
special items 2
3,302
3,359
+ 1.7
5,639
EBITDA 3
3,936
4,502
+ 14.4
6,916
EBITDA before
special items 2
4,612
4,648
+ 0.8
8,280
-
20.8%
GROUP SALES
Sales of the Bayer Group increased by 2.0 percent in the first
half of 2013 to €20,626 million. Bayer HealthCare posted a
3.1 percent increase in sales to €9,243 million. Both segments,
Pharmaceuticals (+3.8 percent) and Consumer Health (+2.2 percent) achieved gratifying gains. Bayer CropScience also improved sales by a substantial 5.5 percent to €5,156 million. Thus
we succeeded in growing the business despite the late start to
the season in the northern hemisphere. Contributing to the
positive business performance were a favorable market environment and the new products of the Crop Protection business
group. All units of Crop Protection showed positive development. Sales at Bayer MaterialScience were roughly in line with
the first half of the previous year, at €5,650 million (–1.6 percent). Slightly higher selling prices did not fully compensate for
a drop in volumes in Europe.
n fiscal 2012, Bayer had sales of €39,741 million.
1st Half
2012
EBITDA margin before
special items 4
1st Half
2013
Full Year
2012
Change
22.8%
22.5%
Income before
income taxes
1,971
2,643
+ 34.1
3,248
Net income
1,521
2,001
+ 31.6
2,403
1,84
2,42
+ 31.5
2,90
Earnings per share (€) 5
Core earnings
per share (€) 6
ross cash o
et cash o
7
8
Capital expenditures *
Research and
development expenses
Dividend per
Bayer AG share (€)
3.12
3.24
+ 3.8
5.30
2,824
3,487
+ 23.5
4,556
1,638
1,863
+ 13.7
4,531
700
867
+ 23.9
1,930
1,450
1,498
+ 3.3
3,013
-
-
-
1.90
ash out o s for additions to intan i le assets, property, plant and e uipment
For notes see page 44
EARNINGS
ebit improved by 29.0 percent in the first half of 2013 to
€3,058 million. Net special items amounted to minus €301 million. ebit before special items rose by 1.7 percent to €3,359 million. ebitda before special items came in slightly ahead of the
prior-year period at €4,648 million ross cash o advanced y
23.5 percent to €3,487 million et cash o rose y 13.7 percent to €1,863 million. Bayer recorded net income of €2,001 million. Earnings per share improved to €2.42, and core earnings
per share to €3.24.
Sales by Segment, 1st Half 2013 (2012 in parentheses)
27%
(28%)
MaterialScience
3%
(3%)
Reconciliation
45%
(45%)
HealthCare
25%
(24%)
CropScience
www.publications.bayer.com
Pharmaceuticals 26%
(26%)
Consumer Health 19%
(19%)
13
14
Investor Information
Bayer Names | Figures | Facts
Investor Information
Performance of Bayer Stock over the Past Twelve Months
indexed; 100 = closing price on June 30, 2012, source: Bloomberg
Bayer stock closed the second quarter of 2013 at €81.93. The
yield for the quarter, including the dividend of €1.90 per share
paid on April 29, 2013, was +4.2 percent. Thus Bayer stock outperformed both the dax and the euro stoxx 50 (performance
index).
he yield on ayer stoc for the first half of 2013, including
the above dividend, was +16.7 percent. The dax ended the first
half of 2013 at 7,959 points, up 4.6 percent. The euro stoxx 50
(performance index) rose by 1.1 percent during this period,
closing at 4,678 points.
160
150
140
130
120
110
100
90
80
July 12 Aug 12 Sept 12 Oct 12 Nov 12 Dec 12 Jan 13 Feb 13 Mar 13 Apr 13 May 13 June 13
Dividends Per Share
SUSTAINABLE INVESTMENT
In 2012 ayer a ain ualified for inclusion in ma or sustaina ility
indices that assess companies on the basis of economic, ecological and social criteria. Bayer stock is represented, for example, in the Dow Jones Sustainability World and Europe indices,
the ftse4Good Global and Europe indices and the nyse Euronext
Low Carbon Europe 100 Index. In 2012 the Carbon Disclosure
Project (cdp) included Bayer in its Carbon Disclosure Leadership
Index (cdli) for the eighth consecutive year. This time Bayer
arnered the overall first place across all industry sectors ointly
with another company. In addition, Bayer was again included in
the Carbon Performance Leadership Index (cpli) with an “a”
rating in recognition of its efforts to reduce co2 emissions.
dj euro stoxx 50 +18.4%
dax +24.0%
Bayer +47.7%
A long-term investor who purchased Bayer shares for €10,000
five years a o and reinvested all dividends ould have seen the
value of the position grow to €13,316 as of December 31, 2012,
giving an average annual return of 5.9 percent.
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
€
€
€
€
€
€
€
€
€
€
0.50
0.55
0.95
1.00
1.35
1.40
1.40
1.50
1.65
1.90
2.2
2.0
1.8
1.6
1.4
1.2
1.0
0.8
0.6
0.4
0.2
0
DIVIDEND INCREASED TO €1.90 PER SHARE
A dividend of €1.90 per share as paid for fiscal 2012, resulting
in a total dividend payment of €1,571 million. The dividend
yield calculated on the share price of €71.89 at year end 2012
amounted to 2.6 percent.
www.investor.bayer.com
Total Dividend Payments
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
€ million
€ million
€ million
€ million
€ million
€ million
€ million
€ million
€ million
€ million
365
402
694
764
1,032 1,070
1,158
1,240 1,364
1,571
15
16
Bayer HealthCare
Bayer Names | Figures | Facts
Bayer HealthCare is among the world’s foremost innovators in
the field of pharmaceutical and medical products his su group’s mission is to research, develop, manufacture and market
innovative products that improve the health of people and animals throughout the world.
The subgroup has four operating divisions:
Animal Health (veterinary medicines and grooming products);
Consumer Care (over-the-counter medicines and dietary
supplements);
Medical Care (blood glucose monitoring devices, contrast
agents, injection systems for diagnostic and therapeutic
medical procedures);
Pharmaceuticals (prescription medicines).
Bayer HealthCare
BUSINESS DEVELOPMENT
Corporate Data
Company
Bayer HealthCare
Headquarters
hief
ecutive
Leverkusen, Germany
fficer
Divisions
Prof. Wolfgang Plischke
Animal Health
Consumer Care
Sales of Bayer HealthCare rose by 8.4 percent in 2012 to
€18.6 illion ebitda before special items climbed by 7.8 percent
to €5.1 billion. Sales of the Pharmaceuticals segment came in
at €10.8 billion, up 8.6 percent from 2011. The Consumer Care
Division achieved sales growth of 9.0 percent to €3.9 billion.
Sales of the Medical Care Division rose by 6.1 percent in 2012 to
€2.7 billion. The Animal Health Division lifted sales by 9.9 percent to €1.3 billion.
Medical Care
Pharmaceuticals
Sales
€18,612 million
EBITDA before special items *
€5,068 million
R&D expenses
€1,962 million
Employees
Bayer HealthCare achieved sales of €9,243 million in the first half
of 2013.
55,300
as of December 31, 2012
* For notes see page 44
Figures | Facts
www.bayerhealthcare.com
Sales
€ million
2011
2012
17,169
18,612
Number of employees
Prof. Wolfgang Plischke
Interim CEO of Bayer
HealthCare (see also page 5)
2011
2012
Research and development expenses
The image above shows
a blood clot.
2011
2012
Employees
55,700
55,300
€ million
1,948
1,962
17
18
Bayer HealthCare
Bayer Names | Figures | Facts
RESEARCH AND DEVELOPMENT ACTIVITIES
In 2012 Bayer HealthCare, with r&d spending of about €2.0 billion, accounted for 65.1 percent of all r&d expenditures by the
Bayer Group. Research and development at Bayer HealthCare
focus on identifying and developing new active substances to
treat diseases with a high unmet medical need.
The Pharmaceuticals Division carries out research and product
development mainly in the fields of ardiolo y, ncolo y,
Women’s Healthcare and Hematology. Other areas of focus
are the therapeutic areas of in ammation and ophthalmolo y
Recent examples of the results of pharmaceutical research are:
XareltoTM: drug product for the prevention and treatment of
venous thromboembolism and for stroke prevention in patients
ith atrial fi rillation
• e
yleaTM: drug product for the treatment of various eye
diseases, such as wet age-related macular degeneration;
ofigoTM: treatment of bone metastases in hormone-refractory
prostate cancer;
riociguat: drug product for the treatment of two different
forms of life-threatening pulmonary hypertension.
Best-selling products *
AdalatTM (drug for the treatment of hypertension)
AdvantageTM line of ea control products for do s and cats
AspirinTM (pain reliever based on acetylsalicylic acid)
AvaloxTM / AveloxTM (drug to treat respiratory tract infections)
BetaferonTM / BetaseronTM (specialty medicine to treat multiple sclerosis)
ContourTM (umbrella brand for blood glucose monitoring systems
and services)
GlucobayTM (drug for the treatment of diabetes)
KogenateTM (hemophilia treatment)
LevitraTM (erectile dysfunction treatment)
MirenaTM (hormonal contraceptive)
NexavarTM (drug to treat kidney and liver cancer)
YAZ TM / YasminTM / YasminelleTM (hormonal contraceptives)
as of December 31, 2012
* in alphabetical order
Research and development in the Consumer Care Division focus
on developing non-prescription medications, medical skincare
products and nutritional supplements to market maturity.
Research in the Medical Care Division concentrates on blood
glucose monitoring and the continuing development of contrast
agents and medical equipment used in the diagnosis or treatment of various diseases.
The Animal Health Division focuses its research and development activities on antibiotics and antiparasitics, as well as on
active substances to treat non-infectious disorders in animals.
Creating value together
From Wuppertal to Berlin and from San Francisco to Beijing, Bayer’s
researchers are looking for new active substances to treat diseases
with a high unmet medical need. They are networked with leading universities, public research institutions and partner companies worldwide to jointly turn new ideas into innovative products.
In the laboratory of OncoMed Pharmaceuticals in
Redwood City, California, Angie Park of OncoMed and
Dr. Peter Nell from Bayer HealthCare discuss a test
apparatus. Bayer entered into a strategic alliance with
U.S. company OncoMed in 2010 to develop a new class
of drugs to target cancer stem cells.
19
20
Bayer CropScience
Bayer Names | Figures | Facts
Bayer CropScience offers its customers an outstanding range of
products including high-value seeds, innovative crop protection
solutions based on chemical and biological modes of action, and
extensive service back-up for modern, sustainable agriculture.
A further focus is on non-agricultural applications.
The business of Bayer CropScience is organized into two
operating segments: Crop Protection / Seeds and Environmental
Science. Crop Protection / Seeds markets a portfolio of highvalue seeds and traits along with innovative chemical and biological pest management solutions, at the same time offering
extensive service backup for modern, sustainable agriculture.
Environmental Science focuses on non-agricultural applications,
with a broad portfolio of pest control products and services for
areas ranging from the home and garden sector to forestry.
Bayer CropScience
BUSINESS DEVELOPMENT
Corporate Data
Company
Bayer CropScience
Headquarters
hief
ecutive
Monheim, Germany
fficer
Business groups
Liam Condon
Crop Protection / Seeds
Environmental Science
Sales
€8,383 million
EBITDA before special items *
€2,008 million
R&D expenses
Employees
Bayer CropScience improved sales in 2012 by 15.5 percent to
around €8.4 billion. ebitda before special items rose by 21.4 percent to about €2.0 billion. Sales of Crop Protection / Seeds
climbed by 16.2 percent in 2012 to roughly €7.7 billion. Sales of
the Environmental Science business unit advanced by 8.6 percent to €0.7 billion.
Bayer CropScience posted sales of €5,156 million in the first half
of 2013.
€782 million
20,800
as of December 31, 2012
* For notes see page 44
Figures | Facts
www.bayercropscience.com
Sales
€ million
2011
2012
7,255
8,383
Number of employees
Liam Condon
Chief Executive
fficer
2011
2012
Research and development expenses
The image above shows part of the
surface of a soybean plant leaf with a
rust fungus spore.
2011
2012
Employees
21,000
20,800
€ million
723
782
21
22
Bayer CropScience
Bayer Names | Figures | Facts
RESEARCH AND DEVELOPMENT ACTIVITIES
Best-selling products *
In 2012, €782 million, or 26.0 percent of the Bayer Group’s
research and development budget, was spent at Bayer CropScience.
AdengoTM (herbicide)
One of the aims of Bayer CropScience is to offer its customers
tailored and innovative solutions for selected crops along the
entire value chain, and in doing so to support sustainable agriculture and help to feed the world population. To achieve this
aim, Bayer CropScience is investing heavily to research and
develop new products, focusing increasingly on seed and new
growth areas such as plant health and stress tolerance.
Recent examples of active ingredients to emerge from research
at Bayer CropScience are:
BastaTM / LibertyTM (herbicides)
Bayer GardenTM / Bayer Advanced TM
(home and garden products for consumers)
BeltTM (insecticide)
onfidorTM (insecticide)
FiberMaxTM / StonevilleTM (cotton seed)
GauchoTM (insecticide)
InVigorTM (summer canola seed)
LunaTM (fungicide)
MoventoTM (insecticide)
as of December 31, 2012
* in alphabetical order
upyradifurone (SivantoTM): effective against sucking pests
such as aphids or hite ies in fruit and ve eta les crops
triafamone: new rice herbicide to control a variety of weeds;
also suitable for pre-emergence application.
Bayer CropScience has assembled a global network of research
and industry partners from diverse segments of the agriculture
industry, chemical and biological research, and the food industry. These cross-industry partnerships enable us to better understand and do justice to the needs of our customers over the long
term.
Partnerships to feed the growing
world population
Seeds, chemical and biological crop protection products and services:
Bayer CropScience already offers comprehensive solutions for
farmers. Targeted partnerships are opening up new ways to sustainably feed the growing world population.
Bayer scientists are working with Israeli company
Evogene to produce healthy wheat that delivers high
yields despite drought and heat. The picture shows
An Michiels from Bayer CropScience and Evogene CEO
Ofer Haviv in a greenhouse in Rehovot, Israel.
23
24
Bayer MaterialScience
Bayer Names | Figures | Facts
Bayer MaterialScience is a renowned supplier of high-tech
polymers and develops innovative product solutions for a wide
variety of everyday uses. Products holding leading positions on
the world market account for a large proportion of its sales.
The subgroup comprises three business units:
Polyurethanes;
Polycarbonates;
Coatings, Adhesives, Specialties
along with the Industrial Operations unit.
BUSINESS DEVELOPMENT
Bayer MaterialScience
Corporate Data
Company
Bayer MaterialScience
Headquarters
hief
ecutive
Leverkusen, Germany
fficer
Business Units
Patrick Thomas
Polyurethanes
Sales of Bayer MaterialScience rose by 6.2 percent in 2012 to
€11.5 billion. This growth was mainly the result of an overall
increase in volumes, hich ere at ith the previous year in
Europe but posted good gains in the other regions. In addition,
e ere a le to raise prices in all re ions e cept sia acific
ebitda before special items advanced by 6.8 percent to €1.3 billion. The Polyurethanes business unit raised sales by 11.9 percent to around €6.0 billion. Polycarbonates posted sales of
€2.8 illion, do n 2.4 percent. Sales in the Coatings, Adhesives,
Specialties business unit moved forward by 2.5 percent to
roughly €2.0 billion. Industrial Operations reported sales of
about €0.7 billion, 8.2 percent more than in the prior year.
Polycarbonates
Coatings, Adhesives, Specialties
Sales
EBITDA before special items *
R&D expenses
Employees
€11,503 million
Bayer MaterialScience achieved sales of €5,650 million in the
first half of 2013.
€1,251 million
€242 million
14,500
as of December 31, 2012
* For notes see page 44
Figures | Facts
www.materialscience.bayer.com
Sales
€ million
2011
2012
10,832
11,503
Number of employees
Patrick Thomas
Chief Executive
fficer
2011
2012
Research and development expenses
The image above shows
a cross section of a e i le
polyurethane foam.
2011
2012
Employees
14,800
14,500
€ million
237
242
25
26
Bayer MaterialScience
Bayer Names | Figures | Facts
RESEARCH AND DEVELOPMENT ACTIVITIES
In 2012, Bayer MaterialScience spent €242 million for research
and development, thus accounting for roughly 8.0 percent of the
Bayer Group’s total research and development expenses. The subgroup’s research activities are focused in part on the development
of plastics manufacturing processes that conserve energy and
resources. In addition, the subgroup works closely with customers
to develop new applications for high-tech materials that can help
to improve ener y and resource efficiency or safety, for e ample
Important products *
Bayblend TM (brand name for polymer blends based on polycarbonate and
acrylonitrile-butadiene-styrene)
BaydurTM (polyurethane system for appliance housings, medical equipment,
sports goods, sanitary items and furniture)
Bay e TM (family of elastic polyurethane systems with customizable properties for a range of applications)
BayhydrolTM (raw materials for waterborne coatings)
BayhydurTM (raw materials for waterborne coatings)
BaythermTM (polyurethane system for high-performance insulation)
In the Polyurethanes; Polycarbonates; and Coatings, Adhesives,
Specialties business units, the latest technologies and production
processes are employed to create new products and new applications in cooperation with customers and other external partners.
The focus in the Polyurethanes business unit is on further increasin the efficiency of ri id polyurethane foam as an insulatin material against cold and heat. Rigid polyurethane foam helps to reduce
energy consumption and protect the climate, especially in the construction industry and along the cold storage chain. The subgroup’s
innovations are geared toward further enhancing the material’s insulatin properties and optimi in ame retardancy in particular
Other results of research include:
DesmodurTM / DesmophenTM (coating raw materials for automotive and
industrial coatin s and anti corrosion systems ra materials for e i le and
rigid foams)
DesmopanTM (thermoplastic polyurethanes for a variety of high-tech
applications)
MakrolonTM (transparent, impact-resistant polycarbonate for CDs, DVDs,
automotive applications, architectural glazing, and applications in the
electrical / electronics industry)
as of December 31, 2012
* in alphabetical order
BaythermTM Microcell: an innovative material that makes refrigerated appliances more ener y efficient
Bay e TM Lightweight: reduces the weight of car body parts by
up to 30 percent;
Dream Production: In this project, Bayer has achieved the
catalytic conversion of carbon dioxide on a pilot-plant scale for
the first time to ether ith partners includin rwth Aachen
University. It is intended to use carbon dioxide to replace fossil
feedstocks in the manufacture of high-performance materials.
The planning process for the construction of a production
facility has begun.
Innovations for global challenges
ner y e ficiency is a ey topic o this century and is especia y
relevant for the millions of residential buildings around the world.
Innovative insulation can help more than anything else to reduce
buildings’ energy requirements and greenhouse gas emissions.
Bayer MaterialScience is working with its partners to develop more
and more new products and solutions to protect against heat and
cold – in the construction and other sectors.
While viewing a projection screen in the showroom at
InnovationCity in Bottrop, Germany, Thomas Adenauer
(right) from Bayer MaterialScience and investor Oliver
Helmke discuss the blueprint for an office building that is
being renovated to enhance its energy efficiency as part
of the EcoCommercial Building Program.
27
28
Service Companies
Bayer Names | Figures | Facts
Service Companies
Corporate Data
The central functions serving the Bayer subgroups’ business
operations are organized into three service companies:
Company
Bayer Business Services GmbH
Headquarters
Leverkusen, Germany
Chairman of the
Executive Board Daniel Hartert
Employees
4,900 *
Services
IT and business services
BAYER BUSINESS SERVICES
Bayer Business Services is the Bayer Group’s global competence center for it and business services. Its portfolio is
focused on services in the core areas of it infrastructure and
applications, procurement and logistics, human resources and
mana ement services, and finance and accountin
www.business-services.bayer.com
Daniel Hartert
Chairman
Corporate Data
Company
Bayer Technology Services GmbH
Headquarters
Leverkusen, Germany
Managing
Director
Dr. Dirk Van Meirvenne
BAYER TECHNOLOGY SERVICES
Employees
2,400*
Bayer Technology Services, the global technological backbone
and a major innovation driver of the Bayer Group, is engaged in
process development and in process and plant engineering, construction and optimization. Bayer Technology Services is the
gateway to the Bayer Group for young engineers.
Services
Technological solutions for processes,
plants and products
Dr. Dirk Van Meirvenne
Managing Director
www.bayertechnology.com
Corporate Data
CURRENTA
Currenta offers services for the chemical industry including
utility supply, waste management, infrastructure, safety,
security, analytics and vocational training. This service company – a joint venture between Bayer and Lanxess – operates
the chempark sites in Leverkusen, Dormagen and KrefeldUerdingen, Germany.
Company
Currenta GmbH & Co. OHG
Headquarters
Leverkusen, Germany
Chairman of the
Executive Board Dr. Günter Hilken
Employees
5,300 *
Services
Services for the chemical industry;
management and operation
of CHEMPARK
Dr. Günter Hilken
Chairman
www.currenta.com
employees on either permanent or fi ed term contracts as of
ecem er
,
29
30
Research and Development
Bayer Names | Figures | Facts
Research and Development
Innovation is the key driver of the Bayer Group’s future growth,
which is why the company focuses on research and development. In 2012, Bayer spent €3,013 million on research and development. This was equivalent to 7.6 percent of sales. The number of employees working in research and development units
worldwide was 12,900.
The importance of global networking and collaboration – both
among the units of the enterprise and with external companies
and organizations – is steadily increasing. At Bayer, the Life
Sciences subgroups – HealthCare and CropScience – therefore
work particularly closely together. We expect common research
projects and the joint use of technology platforms to stimulate
innovations for the improvement of human, animal and plant
health. In addition, research projects with external partners
from science and industry form a key component of Bayer’s innovation strategy. These collaborations and alliances with leading universities, public research institutions and partner companies are supplemented by crowdsourcing, incubators like the
CoLaborator™ in the United States and Berlin, and science hubs
in emerging regions such as Asia to tap into external innovative
potential using the open innovation approach.
Together with the subgroups, Bayer Technology Services is
developin ne ener y and resource efficient production processes to safeguard technology and cost leadership over the
long term. An example is polymer synthesis for Bayer MaterialScience. Centralized development work on technologies relevant
to more than one subgroup, such as biotechnology or expertise
in mathematical simulation and statistical data analysis, helps
Bayer HealthCare and Bayer CropScience to speed up the development of new products. This also includes the development of
entirely new production concepts at facilities such as the invite
research center, a collaborative venture between Bayer Technolo y ervices and ortmund echnical niversity e
e i le,
modular production concepts being developed for Bayer HealthCare are an example of this.
Research and Development Expenses by Subgroup
(2011 in parentheses)
ith stron and efficient research and development, an international network of partners and a focus on growth areas and
markets, Bayer is laying the foundations for its future success.
The company’s activities remain centered on its customers’
needs – true to the mission “Bayer: Science For A Better Life.”
1% (1%)
8% (8%)
Reconciliation
Bayer MaterialScience
RESEARCH IN THE THREE SUBGROUPS
Of the Group’s entire research and development expenditures in
2012, Bayer HealthCare accounted for 65.0 percent, Bayer CropScience for 26.0 percent and Bayer MaterialScience for 8.0 percent.
Further information on each subgroup’s research and development
activities is provided in the respective chapter of this brochure.
26% (25%)
Bayer CropScience
BAYER TECHNOLOGY SERVICES
Bayer Technology Services is an important innovation partner
for the entire Bayer Group with respect to research, development
and engineering. All Bayer subgroups work closely with this
service company worldwide on technology solutions, particularly
in the fields of process technolo y, plant en ineerin , automation and product development.
as of December 31, 2012
www.bayer.com > innovation
65% (66%)
Bayer HealthCare
31
32
Employees
Bayer Names | Figures | Facts
Employees
On June 30, 2013, the Bayer Group employed 113,000 people
worldwide (December 31, 2012: 110,500). The company had around
35,000 employees in Germany (December 31, 2012: 34,600).
Personnel expenses rose by 5.5 percent in 2012 to approximately
€9.2 billion.
VOCATIONAL TR AINING AND RECRUITING
As an employer, Bayer endeavors to appeal to the best and most
talented people worldwide and to retain employees for long
periods by providing good development opportunities, a modern
working environment and competitive compensation. In 2012
this enabled the company to hire a total of more than 4,600
academically ualified specialists and mana ers orld ide
Approximately 700 university graduates were recruited in Brazil
alone, more than 600 in India and about 400 each in China,
Germany and Russia. In 2012 more than 17,000 new people were
hired across all occupations. In addition, some 3,800 challenging internships were awarded to talented young students worldwide to give them pre-graduation insight into the variety of
career opportunities at Bayer. Such young people often return to
the company as employees at a later date. Apart from the hiring
of university graduates, Bayer’s own training programs for
young people are among the most important steps the company
takes to guard against a possible shortage of specialists due to
demographic change. Once again in 2012, more than 900 young
people entered training programs in a total of over 30 occupations at Bayer’s sites in Germany.
setting base salaries in line with the demands and responsibilities of each position. These salaries are supplemented by
performance-related compensation components and extensive
ancillary enefits
More than €700 million in variable bonus awards was paid out
to employees under the Group-wide short-term incentive (sti)
program alone for the year 2012. Included in the extensive range
of ancillary enefits in many countries are various stoc participation programs that enable employees to purchase Bayer stock
at a discount, giving them an additional opportunity to share in
the company’s economic success.
Employee Data
Dec. 31,
2011
FTE
FTE
Europe
53,600
52,300
North America
15,800
15,300
26,000
26,700
16,400
16,200
Production
47,600
45,700
Sales
41,800
42,800
Research and development
13,300
12,900
Employees by region
sia
acific
Latin America / Middle East / Africa
Employees by corporate function
General administration
ADVANCING KNOWLEDGE AND LEADERSHIP SKILLS
Total
Providing training for employees is fundamental both to
talent management and to addressing the consequences of
demographic change. In 2012 Bayer maintained its offering of
advanced training courses for employees at a high level worldwide, adding a number of new features. The company’s training
programs not only build on employees’ specialist knowledge,
but help to develop leadership skills. A further focus is on virtual
learning.
Trainees
EMPLOYEE COMPENSATION AND BENEFITS
An important principle of Bayer’s human resources policy is to
link employees’ compensation to their performance and enable
them to share in the company’s success. Regular benchmarking
against competitors and a globally standardized system help in
Dec. 31,
2012
Proportion of women in senior management
Proportion of full-time employees with
contractually agreed working time not exceeding
48 hours per week
9,100
9,100
111,800
110,500
2,500
2,500
%
%
22
23
100
100
Proportion of employees with health insurance
94
94
Proportion of employees eligible for a company
pension plan or company financed retirement
enefits
69
66
Proportion of employees covered by collective
agreements on pay and conditions
54
53
fi ures restated
he num er of employees on either permanent or fi ed term contracts is stated in full time
equivalents (FTE), with part-time employees included on a pro-rated basis in line with their
contractual working hours. (as of December 31, 2012)
33
34
Sustainability
Sustainability – which to us essentially means future viability –
forms an integral part of our business strategy. Together with
our life values, our mission “Bayer: Science For A Better Life”
serves as the foundation for our sustainable activities. We are
convinced that we can only achieve lasting commercial success if
we balance economic growth with ecological and social responsibility. In this we are guided by long-term values. To underline
this mission, we have committed to international sustainability
initiatives such as the u.n. Global Compact and Responsible
Care™. The clear goal of our sustainability strategy is to create
business opportunities for our company while at the same time
eneratin economic, ecolo ical and social enefits his e do
on the basis of the following elements:
35
Sustainability
Bayer Names | Figures | Facts
entire value chain. These targets also include our ambitious
long-term goals for reducing greenhouse gas emissions.
ACHIEVEMENTS AND KEY INDICATORS
We regularly review our performance in the areas of health, safety and environment on the basis of key performance indicators.
Material and energy consumption and emissions are determined
mainly by the manufactured sales volume. We use this reference
parameter to evaluate ener y and resource efficiency espite
the 2.4 percent growth in manufactured sales volume to 11.2 million metric tons in 2012, we succeeded in improving many kpis,
although phosphate and nitrogen levels in wastewater increased.
The volume of hazardous waste again considerably exceeded the
previous year s fi ure due to a round ater and soil remediation
Key Performance Indicators
Our business: Sustainability is a key element of both the
Bayer Group’s strategy and the business strategies of the
three subgroups and the service companies. Sustainability
permeates all aspects of entrepreneurial activity in the Bayer
Group, particularly through innovative processes and products. Health care and nutrition are essential to the well-being
of society, as are innovative, high-tech materials. Bayer
HealthCare, Bayer CropScience and Bayer MaterialScience
each possess an innovative and viable product portfolio that
can ma e si nificant contri utions in this respect and contribute to sustainable development around the globe.
Our license to operate: Responsible corporate governance
that minimizes our business risks forms the foundation for
Bayer’s business activities. Our focus is on acting responsibly
in the areas of corporate compliance, human resources policy,
product stewardship, occupational health, environmental
protection, safety and supplier management as set forth in
detail in internal Group regulations. These include the Bayer
Sustainable Development Policy; our Human Rights Position,
which also covers working conditions; the Corporate Compliance Policy; our Supplier Code of Conduct; the Responsible
Marketing & Sales Policy; and the revised Directive on
Process and Plant Safety.
Targets and indicators serve to operationalize our sustainability
strategy. With our “Targets 2015,” we aim to integrate sustainability even more closely into our business activities along the
www.sustainability.bayer.com
Category
Key Performance Indicators
for Health, Safety and Environment
Health and
safety
Occupational injuries to Bayer employees
with lost workdays (LTRIR) *
0.31
0,27
Reportable occupational injuries to
Bayer employees (RIR) *
Emissions **
Waste **
Use of
resources **
2011
2012
0.56
0.49
Environmental incidents
3
5
Transportation incidents
7
6
Direct greenhouse gas emissions
(CO2 equivalents in million metric tons) ***
4.23
4.24
Indirect greenhouse gas emissions
(CO2 equivalents in million metric tons) ***
3.92
4.12
Volatile organic compounds (VOC)
(thousand metric tons / year)
2.69
2.60
Total phosphorus in waste water
(thousand metric tons / year)
0.08
0.15
Total nitrogen in waste water
(thousand metric tons / year)
0.53
0.70
Total organic carbon (TOC)
(thousand metric tons / year)
1.50
1.42
Hazardous waste generated
(million metric tons / year)
0.47
0.60
a ardous aste landfilled
(million metric tons / year)
0.12
0.18
Water use (million m3 / year) ****
411
384
Primary energy use for generating
steam and electricity
(petajoules [1015 joules] / year)
50.10
49.05
Secondary energy use for generating
steam, electricity and refrigeration
(petajoules [1015 joules] / year)
34.85
34.14
*
(LT)RIR = (Lost Time) Recordable Incident Rate
** Environmental indicators are determined at all production sites.
*** as per Greenhouse Gas Protocol
fi ure restated ee ustaina le evelopment eport
, pa e
36
Sustainability
Bayer Names | Figures | Facts
project at one of our sites in India. This project was completed
earlier than planned at the end of 2012. Any incidents are
analyzed and evaluated so that steps can be taken to prevent a
recurrence. In 2012 the number of environmental incidents rose
to five ransport accidents sho ed a sli ht decline n 2012 we
further lowered both the Lost Time Recordable Incident Rate
(ltrir), which is based on 200,000 employee hours worked and
includes illnesses, and the Recordable Incident Rate (rir) for
occupational injuries requiring medical treatment.
Selected Memberships
Global Compact
Founding member of the u.n. corporate
responsibility initiative for a sustainable world
Responsible Care Global Charter
Initial signatory to the chemical industry’s global
charter for sustainable development and Responsible
Care
World Business Council for
Sustainable Development
Active member since 1997
SOCIAL COMMITMENT
Bayer’s social commitment is an established part of our sustainability strategy and corporate policy. Our funding activities also
contribute to a positive business environment. Our social commitment is re ected in a ran e of pro ects in many parts of the
orld in the three main fields of education and research, health
and social needs, and sports and culture. Some of these projects
have been ongoing for many years. In 2012 Bayer provided some
€49 million for this purpose.
The funding programs of the Bayer Science & Education Foundation cover the entire scientific trainin and career path n 2012
the foundation approved total funding of about €1.6 million for
dedicated school students, innovative school projects, ambitious
trainees, exceptional university students, outstanding young
scientists and leading researchers. With its global commitment
to improving social conditions and health care, Bayer aims to
promote stability in the communities near its sites and help to
solve global health challenges. In a joint project with the Chinese
government, for example, Bayer supports the provision of medical care to people in the poorer rural areas of western China.
Under the slogan “Go West,” the company provides continuing
education opportunities for general practitioners, equips hospitals and instructs their operators in hospital management.
The company’s offerings in the areas of recreational, youth and
disabled sports, as well as the Bayer Arts & Culture program and
Bayer’s other special-interest clubs, have contributed to the attractiveness of the company’s locations for more than a century,
enefitin employees and other citi ens ali e
“econsense” – sustainable development forum
of German industry
Founding member of the industry-wide initiative for
sustainable development
Bundesdeutscher Arbeitskreis
für Umweltbewusstes
Management e. V.
b.a.u.m.
Member of the German Association of
Environmental Management (b.a.u.m.) since 2010
Global Reporting Initiative
Active supporter as an organizational stakeholder
Selected Projects
unep
Bayer’s partnership with the United Nations
Environment Programme (unep) has set new standards in public-private partnerships. For example,
young people from 19 countries on three continents
participate in the environmental education program
“Bayer Young Environmental Envoy in Partnership
with unep.”
Making Science Make Sense
The international Bayer education initiative
“Making Science Make Sense” is implemented in
14 countries around the world. Bayer employees
donate their time to illustrate the fascination and
practical importance of science to elementary
school students through experiments.
tb Alliance
n the fi ht a ainst tu erculosis, ayer is cooperating with the Global Alliance for tb Drug Development, a u.s. non profit or ani ation, ith the aim of
developing a new drug that reduces treatment
times.
www.sustainability.bayer.com
37
38
History
Bayer Names | Figures | Facts
www.bayer.com > about bayer > history
History
1939
headquarters of
Bayer CropScience) in
Monheim.
19 CENTURY
th
1863
On August 1,
businessman Friedrich
Bayer and master
dyer Johann Friedrich
Weskott establish a
dyestuffs factory in
Barmen, now part of
the city of Wuppertal.
1881
1891
On July 1, the
descendants of Bayer
and Weskott establish
the joint stock company
Farbenfabriken vorm.
Friedr. Bayer & Co.
The Leverkusen site is
purchased.
1986
1897
Bayer’s entire u.s.
activities are consolidated under the
management holding
company Bayer usa
Inc., Pittsburgh.
1884
Bayer scientist
Dr. Felix Hoffmann
succeeds in synthesizing a chemically pure
and stable form of
acetylsalicylic acid, the
active ingredient of
AspirinTM.
1899
1865
The company founders
purchase an interest in
a coal tar dye factory
in the United States
and begin exporting
intermediates.
The chemist Carl
Duisberg starts his
career with Bayer.
Under his leadership,
the scientists make
groundbreaking
discoveries.
1888
1876
A branch factory is
opened in Moscow.
The company establishes a pharmaceutical department.
AspirinTM is registered
as a trademark and
soon achieves worldwide fame as a painkiller.
20 th CENTURY
Bayer scientist
Gerhard Domagk is
awarded the Nobel
Prize for Medicine for
his discovery of the
antibacterial effects
of sulfonamides
(Prontosil).
ness of Sterling Winthrop, at the same time
regaining full rights to
the Bayer name for all
products and the Bayer
Cross trademark in
the United States and
Canada, which had
been confiscated after
the First World War.
1999
1991
1951
Bayer is re-established
as Farbenfabriken
Bayer AG, changing its
name to Bayer AG in
1972.
Bayer’s Communication Center (BayKomm)
is inaugurated in
Leverkusen.
1973
1994
Ground is broken for
the Brunsbüttel production site and six
years later, in 1979, for
the Agricultural Center
(now the corporate
The first production
facility of Bayer Bitterfeld GmbH comes on
stream. In the same
year, Bayer acquires
the North American
self-medication busi...
...
To mark the 100th birthday of AspirinTM on
March 6, professional
mountaineers wrap
Bayer’s former high-rise
headquarters building in
Leverkusen, transforming it into the “world’s
biggest AspirinTM pack”
and earning the company three entries in
the Guinness Book of
Records.
21st CENTURY
1912
1925
2000
2001
2002
Acquisition of the
polyols business of
u.s.-based Lyondell
Chemical Company
makes Bayer the
world’s biggest producer of raw materials
for polyurethanes.
On December 6, the
company’s management announces plans
to establish independent operating sub sidiaries under the
umbrella of a management holding company.
In June, Bayer
acquires Aventis
CropScience, making
it a world leader in
crop protection.
The company’s headquarters are transferred to Leverkusen.
Farbenfabriken vorm. Friedr. Bayer & Co. merges
with other companies to form I.G. Farbenindustrie
AG. Leverkusen becomes the main production
center of the I.G.’s Lower Rhine operating consortium. As Germany’s most important chemical
company, I.G. Farbenindustrie also becomes
involved in events during the Third Reich. After
the Second World War, the Allies seize and
subsequently break up the I.G. Farben.
39
40
History
Bayer Names | Figures | Facts
2007
21. JAHRHUNDERT
2002
2004
2005
100 years of the Bayer
Cross: in January
the Bayer Group’s
world-famous trademark celebrates its
centennial.
In December, the u.s.
Food and Drug Administration approves
sorafenib (tradename:
Nexavar™), an active
ingredient jointly
developed by Bayer
HealthCare and Onyx
Pharmaceuticals Inc.,
for the treatment of
advanced renal cell
carcinoma.
2004
2006
Bayer CropScience AG
is launched in October
as the first legally
independent Bayer
subgroup.
2003
In February, the
World Health Organization (who) includes
acetylsalicylic acid,
the active ingredient
in Aspirin™, in its
“List of essential
medicines.”
2003
In October, the subgroups Bayer Chemicals AG and Bayer
HealthCare AG and
the service company
Bayer Technology
Services GmbH gain
legal independence as
part of the reorganization of the Bayer
Group. The subgroup
Bayer MaterialScience
AG and the service
companies Bayer Business Services GmbH
and Bayer Industry
Services GmbH & Co.
ohg (now Currenta
GmbH & Co. ohg)
follow in December.
In June, Bayer
becomes the first
private-sector partner
to the United Nations
Environment Programme (unep) in the
area of youth and
environment.
2005
In January, Bayer
completes the acquisition of the Roche consumer health business,
advancing to become
one of the world’s top
three suppliers of
non-prescription medicines.
2005
Lanxess AG is spun off
from the Bayer Group
on January 28. This
company continues
Bayer’s chemicals
business and parts of
its polymers business.
In March, Bayer announces a public takeover offer for Schering
AG, Berlin, Germany.
In July, Bayer gains
control of 92.4 percent
of the approximately
191 million outstanding
shares of Schering AG,
Berlin, Germany. In December, Schering AG,
Berlin, Germany is officially renamed Bayer
Schering Pharma AG.
The company is headquartered in Berlin.
2007
In March it is announced
that the BayArena stadium, home of German
Bundesliga soccer team
Bayer 04 Leverkusen,
is to be modernized and
enlarged to accommodate a crowd of over
30,000.
2007
Centennial celebration: the Bayer Archive
has served as the
company’s “memory”
since March 1907.
development of the
new anticoagulant
rivaroxaban (Xarelto™).
2010
In August Bayer hosts
the Tunza International Youth Conference in
Leverkusen, the first
time this youth environmental summit has
been held in central
Europe. 180 young
people from 85 countries debate global environmental issues.
cathode technology
saves energy and reduces co2 emissions.
2008
In October the world’s
largest mdi production facility goes on
stream in Shanghai.
2009
2007
Centennial celebration:
in September, the 100 th
season of the Bayer
Cultural Affairs Department gets under way.
2007
November sees the
launch of the integrated, Group-wide Bayer
Climate Program. The
aims of this program
include reducing the
company’s co2 emissions.
2008
In June Bayer is
presented with the
2008 Environmental
Award in the category
“Environmentally
Friendly Technologies”
by the Federation of
German Industries
(bdi). Use of the new
oxygen depolarized
...
In November, Bayer
implements its zeroemissions building
concept for the first
time with the opening
of a children’s daycare
center in Monheim,
Germany.
2009
In November, Bayer
CropScience completes the acquisition
of Athenix Corp., a
privately held u.s. biotechnology company.
On October 1,
Dr. Marijn Dekkers
succeeds Werner
Wenning as Chairman
of the Board of Management of Bayer AG.
2011
In February, Bayer
starts up the “Dream
Production” pilot plant
in Leverkusen to
manufacture high-tech
plastics using carbon
dioxide.
2012
In March, Bayer
receives approval from
the Australian Therapeutic Goods Administration (tga) for
eylea™, an eye medicine for the treatment
of wet age-related
macular degeneration.
2013
2009
In December, a Bayer
team wins the German
Future Prize for the
...
Bayer celebrates its
anniversary: numerous
events are held worldwide to mark the company’s 150 th birthday.
41
42
Dialogue
Bayer Names | Figures | Facts
Dialogue
Contacts
Bayer AG
Bayer places great importance on communication, regarding it
as a company’s duty to society and at the same time an essential
tool for shaping its public image. Bayer seeks an open dialogue
on people’s questions and problems in order to ensure credibility, trust and acceptance.
Dr. Herbert Heitmann
[email protected]
Bayer HealthCare
Oliver Renner
[email protected]
Bayer CropScience
Steffen Kurzawa
[email protected]
Bayer MaterialScience
PRINT AND ONLINE PUBLICATIONS
Richard Northcote
Bayer AG issues a range of publications to keep the general
public, employees and stockholders abreast of developments:
Bayer Business Services
Florian Schwalbach
[email protected]
orian sch al ach
ayer com
Bayer Technology Services
Annual Report
Stockholders’ Newsletter
Sustainable Development Report
research scientific ma a ine
direkt (newspaper for employees)
Dr. Arnold Rajathurai
[email protected]
Currenta
Jürgen Gemke
[email protected]
Internet addresses
A comprehensive overview of the Bayer Group and its global
activities can be found on the company’s internet site at
www.bayer.com, which includes an innovative Video Center
with a range of video clips. In addition, the “Bayer magazine”
is a corporate publication in digital form, available as an app for
tablets or in an online version, that provides multimedia insight
into the Bayer world. Bayer also has its own pages on the main
social networks. Further information about the subgroups and
service companies is provided on their respective homepages.
Homepage
www.bayer.com
BayKomm
www.baykomm.bayer.com
Annual Report
www.annualreport.bayer.com
Stockholders’ Newsletter
www.stockholders-newsletter.bayer.com
Sustainable Development Report
www.sustainability.bayer.com
research scientific ma a ine
www.research.bayer.com
Publications
www.publications.bayer.com
News releases
www.press.bayer.com
Magazine
www.magazine.bayer.com
BAYKOMM
Video Center
www.video-center.bayer.com
Another focus of the company’s information offering is the
Bayer Communication Center “BayKomm” in Leverkusen, which
was opened in 1991. BayKomm features exhibition areas and
numerous events devoted to specific su ects isitors can learn
about Bayer’s activities and acquaint themselves with a variety
of scientific topics from the development of ne medicines
and the safeguarding of global harvests to modern materials
that help to conserve natural resources. Also on offer are guided tours to the approximately 300 exhibits, experimental
lectures and projects for school students. In February 2010, a
further “Baylab” laboratory for schoolchildren was opened at
BayKomm. This facility – the company’s fourth Baylab – is designed to arouse the enthusiasm of children and young people
for the world of science. The young visitors to the laboratory
become research scientists for a day.
Facebook
www.facebook.com/bayer
To order print publications
Email
[email protected]
Regular mail
Please use the attached reply card
Communication Center “BayKomm”
Kaiser-Wilhelm-Allee 1b, 51373 Leverkusen
Opening times for visitors without an appointment:
Monday through Friday, 12:00 noon to 6:00 p.m., Sunday 12:00 noon to 5:00 p.m.
(other times by appointment)
BayKomm Service Infoline:
Phone: + 49 214 30 50100
43
44
Masthead
Bayer Names | Figures | Facts
45
MASTHEAD
Published by
Bayer AG, Communications, 51368 Leverkusen, Germany
Editor
Dr. Katrin Schneider, phone +49 214 30 48825
Email: [email protected]
English edition
Currenta GmbH & Co. OHG
Language Service
Bayer on the internet
www.bayer.com
More than 30,000 people attended a grand celebration of Bayer’s
150 th anniversary in the BayArena stadium. Employees, their families
and retirees had traveled to Leverkusen from all over Germany to attend.
During the event, they formed the largest-ever human Bayer cross.
August 2013
since 1863 – innovating for the future
1
2
With our inventions we have contributed much to improving
people’s lives since 1863. To mark its anniversary, Bayer is holding
a series of events and organizing a number of projects worldwide.
While
these
activities
primarily
EBIT
earnin
s efore
financialfocus
result and
ta es on the employees and their
families, Bayer is also celebrating with neighbors, customers,
EBIT before special items and EBITDA efore special items are not defined in the nternational
partners and the scientific community. Find out more about Bayer’s
Financial Reporting Standards and should therefore be regarded only as supplementary
anniversary
on theconsiders
internetEBITDA
at www.bayer.com.
information.
The company
before special items to be a more suitable
indicator of operating performance since it is not affected by depreciation, amortization,
impairments or special items. By reporting this indicator, the company aims to give readers a
clearer picture of the results of operations and ensure greater comparability of data over time.
150
3
EBITDA = EBIT plus amortization and impairment losses on intangible assets and depreciation
and impairment losses on property, plant and equipment, minus impairment loss reversals
4
The EBITDA margin before special items is calculated by dividing EBITDA before special items
by sales.
5
Earnings per share as defined in
6
Core earnings per share are not defined in the nternational inancial eportin tandards
and should therefore be regarded only as supplementary information. The company considers
that this indicator gives readers a clearer picture of the results of operations and ensures
greater comparability of data over time.
7
Gross cash ow income after income ta es, plus income ta es, plus financial result, minus
income taxes paid or accrued, plus depreciation, amortization and impairment losses, minus
impairment loss reversals, plus / minus changes in pension provisions, minus gains / plus losses
on retirements of noncurrent assets, minus gains from the remeasurement of already held
assets in step acquisitions. The change in pension provisions includes the elimination of noncash components of
t also contains enefit payments durin the year
yea rs
8
Net cash ow
cash o
net income divided y the avera e num er of shares
from operatin activities accordin to
Forward-Looking Statements
This publication may contain forward-looking statements based on current assumptions
and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the
actual future results, financial situation, development or performance of the company and
the estimates given here. These factors include those described in Bayer‘s public reports,
which are available on the Bayer website at www.bayer.com. The company assumes no
liability whatsoever to update these forward-looking statements or to conform them to
future events or developments.
Legal Notice
The product names designated with ™ are brands of the Bayer Group or its distribution
partners and are registered trademarks in many countries.